t
Proteome Sciences plc held its Annual General Meeting on 14 May 2026 at 12:00 noon. Chairman Christopher Pearce stated that good progress is being made in service business order levels and that recovery in TMT and reagent sales continues in the first half, following 2025 cuts to US NIH budgets and academic grants. The company also noted significant investment made in the business over the last two years.
| Date | 14 May 2026 |
| Time | 12:00:00 |
| Category | AGMs and other meetings |
| ID | 3451E |
14 May 2026
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Annual General Meeting Statement
At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, made the following statement:
"Good progress is being made in order levels in our services business and the recovery that we hoped for in TMT and reagent sales continues in the first half following the cuts in US NIH budgets and academic grants in 2025.
With the significant investment made in the business over the last 2 years, we believe we are well positioned to deliver substantial returns from our activities in the fast growing field of proteomics."
- Ends -
For further information:
|
Proteome Sciences plc |
|
|
Christopher Pearce, Executive Chairman |
|
|
Dr. Ian Pike, Chief Scientific Officer |
Tel: +44 (0)20 7043 2116 |
|
Richard Dennis, Chief Commercial Officer
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser & Broker) |
|
|
David Hignell/Richard Morrison/Josh Ray (Corporate Finance) Vadim Alexandre (Corporate Broking)
|
Tel: +44 (0) 20 3470 0470 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the selectivity that drugs have to binding one or more proteins in the sample proteome. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
Further information on the Company can be found on its website at: https://www.proteomics.com/
The Company's LEI is 213800Q62ICXANKU2986.
This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.